Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides

Scandinavian Journal of Rheumatology

Volumn 34, Issue 3, 2005, Pages 178-190

  Braun, Jürgen ^a   Baraliakos, X ^b   Brandt, J ^b   Sieper, J ^b  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANEMIA; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; COCCIDIOIDOMYCOSIS; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NEUROPATHY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PATHOGENESIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; REACTIVE ARTHRITIS; RELAPSE; RETROPHARYNGEAL ABSCESS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TUBERCULOSIS; VASCULITIS;

ANTIRHEUMATIC AGENTS; BIOLOGICAL THERAPY; EARLY DIAGNOSIS; HUMANS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22144481690     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740510026599     Document Type: Review

References (141)

1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
2. Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A, et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all, patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 1999;38:831-6.
3. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985;44:359-67.
4. Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J Rheumatol 1999;26:2622-7.
5. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
6. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55.
7. Zink A, Listing J, Klindworth C, Zeidler H. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis 2001;60: 199-206.
8. Boonen A, Chorus A, Miedema H, Van Der Heijde D, Van Der Tempel H, Van Der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8.
9. Chorus AM, Boonen A, Miedema HS, Van Der Linden S. Employment perspectives of patients with ankylosing spondylitis. Ann Rheum Dis 2002;61:693-9.
10. Boonen A, Van Der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-Van Molken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61: 429-37.
11. Boonen A, Van Der Heijde D, Landewe R, Guillemin F, Spoorenberg A, Schouten H, et al. Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann Rheum Dis 2003;62:741-7.
12. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
13. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004;63:1670-2.
14. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:737-51, viii.
15. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995;21:117-28.
16. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002;29:1420-5.
17. Van Tubergen A, Landewe R, Van Der Heijde D, Kidding A, Wolter N, Asscher M, et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001;45:430-8.
18. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002;4:307-21.
19. Braun J, Van Der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investig Drugs 2003;12:1097-109.
20. Maini R, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50: 1051-65.
21. Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003;112:37-53.
22. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
23. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996;8:275-87.
24. Mcgonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998;41:694-700.
25. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45.
26. Muche B, Bollow M, Francois RJ, Sieper J, Hamm B, Braun J. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003;48:1374-84.
27. Laloux L, Voisin MC, Allain J, Martin N, Kerboull L, Chevalier X, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001;60:316-21.
28. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
29. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis - cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59:135-40.
30. Mielants H, Veys EM. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis. J Rheumatol 1985;12:287-93.
31. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
32. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
33. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
34. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44: 2112-17.
35. Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003;17: 185-92.
36. Kruithof E, Van Den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12.
37. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
38. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
39. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailes E, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002;41:1280-5.
40. Collantes-Estevez E, Munoz-Villanueva MC, Canete-Crespillo JD, Sanmarti-Sala R, Gratacos-Masmitja J, Zarco-Montejo P, et al. Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann Rheum Dis 2003;62:1239-40.
41. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
42. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003;62:1218-20.
43. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
44. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
45. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359: 1187-93.
46. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 Feb;52(2):582-91.
47. Van Der Heijde D, Dijkmans B, Geusens P, Sieper J, Dewoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a 24-week randomized, placebo-controlled trial (ASSERT). In, Annual European Congress of Rheumatology, SAT0053, Berlin, Germany.
48. Van Der Heijde D, De Vlam K, Burmester G, Veys E, Han C, Dewoody K, et al. Infliximab improves productivity in employed patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). In, Annual European Congress of Rheumatology, SAT0044, Berlin, Germany.
49. Braun J, Kellner H, Deodhar A, Inman R, Han C, Dewoody K, et al. Infliximab improves quality of life in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Ann Rheum Dis 2004; 63 Suppl I:400.
50. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis. A clinical and imaging study. Ann Rheum Dis 2005;(in press).
51. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
52. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, et al. Persistent clinical response to the anti-TNF antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6.
53. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis (AS) after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44. Epub 2005 Feb 21.
54. Braun J, Van Der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2002;16:573-604.
55. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
56. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
57. Wanders A, Landewé R, Van Der Linden S, Dougados M, Mielants H, Van Der Tempel H, et al. What is the most appropriate scoring method for ankylosing spondylitis in clinical trials? A comparison of the available methods based on the OMERACT filter. In, 67th Annual Scientific Meeting of the American College of Rheumatology, Orlando/FL, USA.
58. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-a antibody infliximab. Ann Rheum Dis 2005; Mar 18; [Epub ahead of print].
59. Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 2004;63:144-8.
60. Van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-30.
61. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
62. D'Agostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 2003;48:523-33.
63. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
64. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48: 1667-75.
65. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
66. Davis J Jr, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum 2004;51:302-4.
67. Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005;44:342-8.
68. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis before and during therapy with etanercept. Ann Rheum Dis 2005;Mar 18 [Epub ahead of print].
69. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005;52:1216-23.
70. Haibel H, Brandt HC, Rudwaleit M, Listing J, Braun J, Kupper H, et al. Preliminary results of an open-label, 12 week trial of adalimumab in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2004;64 Suppl 1:399.
71. Braun J, Sieper J. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin. BioDrugs 2003;17:187-99.
72. Pipitone N, Kingsley GH, Manzo A, Scott DL, Pitzalis C. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford) 2003;42:1138-48.
73. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002;61:298-304.
74. Canete JD, Pablos JL, Sanmarti R, Mallofre C, Marsal S, Maymo J, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004;50:1636-41.
75. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
76. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
77. Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, De Rie MA, Bos JD, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769-73.
78. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
79. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
80. Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003;49:541-5.
81. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39: 2013-20.
82. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
83. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001;26:27-9.
84. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol 2002;16:127-9.
85. Meador R, Hsia E, Kitumnuaypong T, Schumacher HR. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 2002;20:S130-4.
86. Oili KS, Niinisalo H, Korpilahde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scand J Rheumatol 2003;32:122-4.
87. Dougados M, Van Der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
88. Van Den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
89. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002;29:118-22.
90. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004;31:531-8.
91. Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllonen E, Lindgren KA, et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine 2003;28:750-3.
92. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis 2004;63:1120-3.
93. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002;20:S152-7.
94. Ellerin T, Rubin RH, Weinblatt ME. Infections and antitumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
95. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
96. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
97. Baeten D, Kruithof E, Van Den Bosch F, Van Den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
98. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
99. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46: 3151-8.
100. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
101. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
102. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107: 3133-40.
103. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30.
104. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
105. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van Den Bossche N, Van Den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-23.
106. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002;61:375-6.
107. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-8.
108. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004;50:1959-66.
109. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331-5.
110. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. Aids 2004;18:257-64.
111. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
112. Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.
113. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51.
114. Franklin JP, Symmons DP, Silman AJ. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents. Ann Rheum Dis 2005;64:657-8.
115. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
116. Askling J, Fored M, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Hematopoietic malignancies in rheumatoid arthritis. Lymphoma risk and characteristics following TNF-antagonists. Ann Rheum Dis 2005;Apr 20 [Epub ahead of print].
117. Askling J, Fored M, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and following treatment with tnf-antagonists. Ann Rheum Dis 2005;Apr 13 [Epub ahead of print].
118. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11.
119. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004;51: 447-50.
120. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004;6:R264-72.
121. Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. Rheumatology (Oxford) 2004;43: 1072-84.
122. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8.
123. Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-61.
124. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003;30:2287-91.
125. Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003;62:587-8.
126. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.
127. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
128. Maksymowych WP, Jhangri GS, Fitzgerald AA, Leclercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate 60(mg) versus 10(mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
129. Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DT. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002;47:249-54.
130. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
131. Stone MA, Inman RD, Wright JG, Maetzel A. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 2004;51: 316-20.
132. Van Tubergen A, Van Der Heijde D, Anderson J, Landewe R, Dougados M, Braun J, et al. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis 2003;62:215-21.
133. Brandt J, Listing J, Sieper J, Rudwaleit M, Van Der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
134. Brandt J, Listing J, Sieper J, Van Der Heijde D, Braun J. Improvement criteria for treatment with biologics of patients with ankylosing spondylitis - a proposal based on data from a recent randomized trial with the anti-TNFα agent infliximab. Arthritis Rheum 2002;46:380.
135. Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
136. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
137. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004;43:1158-66.
138. Landewe R, Rump B, Van Der Heijde D, Van Der Linden S. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann Rheum Dis 2004;63: 530-4.
139. Braun J, Pham T, Sieper J, Davis J, Van Der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
140. Pham T, Van Der Heijde D, Calin A, Khan MA, Van Der Linden S, Bellamy N, et al. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis 2003;62:812-16.
141. Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994;21:1883-7.